Parkinson's Disease Therapeutics Conference

Attendee arrivals and networking

Mark Frasier, PhD, The Michael J. Fox Foundation

2:55-3:25PM — First Room of Your Choice 
3:35-4:05PM — Second Room of Your Choice 
4:15-4:45PM — Third Room of Your Choice

ROOM OPTIONS

Room A: Advancing Targets to Therapies

Allie Vaina, PhD, The Michael J. Fox Foundation
Gaia Skibinski, PhD, The Michael J. Fox Foundation
Fiona Ducotterd, PhD, University College London
Jonathan Behr, PhD, Advisor to the Michael J. Fox Foundation

Explore how MJFF’s Targets to Therapies initiative can provide industry with the resources to evaluate emerging PD targets and inform decisions about which opportunities to advance.

Room B: PPMI: Advancing Drug Development in Parkinson’s and Rleated Disorders

Catherine Kopil, PhD, The Michael J. Fox Foundation
Kenneth Marek, MD, Institute for Neurodegenerative Disorders
Tanya Simuni, MD, FAAN, Northwestern University Feinberg School of Medicine

Learn how PPMI data, biomarkers and regulatory insights – alongside the Path to Prevention (P2P) platform trial – can inform more successful clinical trials.

Room C: MJFF Biomarker Toolkits & Resources

Ariana Farrand, PhD, The Michael J. Fox Foundation
Christine Swanson Fischer, PhD, The Michael J. Fox Foundation
Katrina Paumier, PhD, Octave Bioscience

Explore MJFF’s biomarker toolkits and resources for measuring key PD biological pathways, and help shape how these drug development tools can better support clinical development.

Room D: Multimodal Data and Cohorts to Enable Precision Medicine

Samantha Hutten, PhD, The Michael J. Fox Foundation
Chris Whelan, PhD, Ignition Scientific
Kendall Van Keuren-Jensen, PhD, TGen

Learn how rapidly expanding multimodal datasets from PPMI, GP2 and other efforts can be leveraged for target discovery, patient stratification, biomarker development and trial design.

Room E: Patient Centered Strategies for Drug Development

Maggie Kuhl, The Michael J. Fox Foundation
Wes Kutler, The Michael J. Fox Foundation

Learn how incorporating patient insights earlier in therapeutic development can strengthen R&D decisions, and how MJFF can help companies engage the patient community along the way.

Networking reception

Arrivals and Breakfast

Sohini Chowdhury, The Michael J. Fox Foundation

9:05-9:15AM — Session Introduction from Session Chair
Magdalene Moran, PhD, Topo Therapeutics

9:15-10:30AM — Company Fast Fire Presentations

9:15-9:30AM — Brain Shuttle-enabled Delivery of a TrkB Agonist Antibody for Disease Modification in Parkinson’s Disease 
Pawel Stocki, PhD, Ossianix

9:30-9:45AM — 20S Proteasome Activation for the Treatment of Parkinson’s Disease 
Diogo Feleciano, PhD, Booster Therapeutics

9:45-10:00AM — Development of Small-molecule Inhibitors of the Mictochondria Permeability Transition Pore for the Treatment of Parkinson’s Disease and ALS   
Richard Rutter, PhD, NRG Therapeutics

10:00-10:15AM — Development of a TRPML1 Agonist for GD-PD and Beyond
Leon Murphy, PhD, Casma Therapeutics

10:15-10:30AM — HER-096: A Subcutaneous CDNF-derived Peptide for Parkinson’s disease— (em dash) Rationale and Phase 1b Results 
Henri Huttunen, PhD, Herantis Pharma Plc

10:40-11:15AM — Panel Discussion

Networking break and poster viewing

11:55-12:05PM — Session Introduction from Session Chair 
Johannes Streffer, MD, Lundbeck

12:05-12:25PM — The Latest on a-Synuclein Imaging
Jamie Eberling, PhD, The Michael J. Fox Foundation

12:25-12:45PM — Detect PD: Proteomic Testing for Development and Progression of a-Synuclein Disease 
Celine Roeder, Queen Mary University of London 
Julia Carrasco Zanini Sanchez, PhD, Queen Mary University of London 

12:45-1:05PM — Polygenic Risk Scores in Neuronal a-Synuclein Disease Stage Progression 
Manuela Tan, PhD, University College London

1:05-1:25PM — Multivariate Latent Disease Progression Modeling in Neuronal a-Synuclein Disease
Barbara Wendelberger, PhD, Berry Consultants

1:30-1:40PM — Closing Remarks & Audience Questions

Lunch, networking break and poster viewing

3:00-3:15PM — Session Introduction from Session Chair
Brian Fiske, PhD, The Michael J. Fox Foundation

3:15-4:00PM — Panel Discussion 
Moderator: Brian Fiske, PhD, The Michael J. Fox Foundation
Panelists: Patrik Brundin, MD, PhD, Roche; Richard Danzinger, Independent Advisor; Joohi Jimenez-Shahed, MD, Mt.Sinai; Maggie Kuhl, The Michael J. Fox Foundation

Sohini Chowdhury, The Michael J. Fox Foundation

Networking reception and poster viewing

National Parkinson’s Project: A Federal Framework to Accelerate Progress Against Parkinson’s Disease and Related Disorders 
Danielle Mutone-Smith, The Michael J. Fox Foundation

Advancing GB1 Biomarkers - The GBA1 Industry Biomarker Consortium 
Fernanda Cerqueira, PhD, The Michael J. Fox Foundation

Accelerating Parkinson’s Disease Research Through Shared Resources 
Nicole Polinski, PhD, The Michael J. Fox Foundation

Cognition Endpoints for Parkinson’s Disease: A Roadmap for Developing Patient-focused Assessment Tools to Accelerate Drug Development 
Chris Edgar, PhD, PCOA

Novel Modeling Approach for Comparing Treatment-naive and Post-treatment Neuronal Synucleinopathy Progression Using Multi-modal PPMI Data 
Piet Aarden, MSc, Novartis

A Dopamine Clock for Biological Staging of Parkinson’s Disease 
Roger Gunn, PhD, XingImaging

Is there a virtual option for the Conference? Will it be recorded?

Unfortunately, we are not livestreaming or recording the Conference. 

Can I present my research at the Conference?

We have already selected our speakers for the conference. Generally, our speakers are nominated and identified by members of MJFF's Research Leadership team who work to craft the programmatic themes for the event. For more information, please email [email protected]. 

Can I present my abstract at the Conference?

Thank you for your interest in presenting at the Conference. We do not accept abstracts for this conference. Poster presenters are by MJFF’s leadership team based on the grants that we fund. For more information, please email [email protected].  

When will the Conference agenda be available?

The agenda will be made available in the Fall.  

How can my organization sponsor the Parkinson’s Disease Therapeutics Conference?

Thank you for your interest in sponsoring the Parkinson’s Disease Therapeutics Conference! You can view our sponsorship opportunities menu here. If you are interested in learning more, please email [email protected].

Where is the Conference taking place?

The Parkinson’s Disease Therapeutics Conference will take place at Quorum by Convene at 1221 Avenue of Americas, New York, NY 10020.

How do I get to the Parkinson’s Disease Therapeutics Conference venue?

Please review this document to find the best route for you to travel to the venue. Upon entrance at 1221 Avenue of the Americas on 49th Street between 6th Ave and 7th Ave, please take the escalator on your right up to the second floor. There you will be greeted by the Convene Welcome Desk and directed to check-in for the Parkinson’s Disease Therapeutics Conference.

How can I find out information about hotels and their rates for this Conference?

When you register, your confirmation email will include information about the hotel block associated with the Conference. If you have questions, please contact [email protected].  

How do I apply for a visa to travel to the United States?

Visa regulations depend on your nationality and country of origin. We suggest you contact your local Consulate for full and official instructions on the specific visa regulations and application procedure that apply to you.

Where can I get a conference invitation letter so that I can apply for a visa?

Invitation letters for visa purposes are available only to registered attendees. If you need an invitation letter, please email [email protected].  

Is it possible to send an official invitation letter directly to my local Consulate?

Unfortunately, we are unable to send invitation letters directly to consulates. Invitation letters are prepared solely for individuals and are emailed directly to them.